Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 Study
View Full Paper
Ask AI
Bookmark
Share
Key Points
Ninety-seven percent achieved an objective response rate, reflecting successful intervention with blinatumomab and ponatinib.
This phase 2 study involved adults over 18 years with B-cell acute lymphoblastic leukemia and demonstrated a significant response.
Following the addition of CNS-directed therapy, rates of central nervous system relapse remained low, supporting treatment strategies.
Adverse events were predominantly mild, with neurotoxicity managed effectively, underscoring the treatment's tolerability.
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Phase 2 study shows high remission rates in adults with Ph+ B-ALL treated with blinatumomab and ponatinib, indicating effective frontline therapy.